Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome

被引:25
作者
Kretschmer, Alexander [1 ]
Tutrone, Ronald [2 ]
Alter, Jason [3 ]
Berg, Elena [1 ]
Fischer, Christian [3 ]
Kumar, Sonia [3 ]
Torkler, Phillipp [3 ]
Tadigotla, Vasisht [3 ]
Donovan, Michael [4 ]
Sant, Grannum [3 ]
Skog, Johan [3 ]
Noerholm, Mikkel [3 ]
机构
[1] Univ Munich, Dept Urol, LMU Klinikum, Munich, Germany
[2] United Urol Grp, Towson, MD USA
[3] Exosome Diagnost, 266 2nd Ave 200, Waltham, MA 02451 USA
[4] Univ Miami, Dept Pathol, Miami, FL USA
关键词
Exosomes; PSA-gray-zone; Urine-biomarker; Radical-prostatectomy; Upgrading; Prostate cancer; PROSTATE-CANCER; GENOMIC HETEROGENEITY; ASSAY;
D O I
10.1007/s00345-022-03937-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose ExoDx Prostate IntelliScore (EPI) is a non-invasive urine exosome RNA-based test for risk assessment of high-grade prostate cancer. We evaluated the association of pre-biopsy test results with post-radical prostatectomy (RP) outcomes to understand the potential utility of EPI to inform invasive treatment vs active surveillance (AS) decisions. Methods Urine samples were collected from 2066 men scheduled for initial biopsy with PSA between 2 and 10 ng/mL, no history of prostate cancer, and >= 50 years across multiple clinical studies. 310 men proceeded to RP, of which 111 patients had Gleason group grade 1 (GG1) at biopsy and would have been potential candidates for AS. We compared pre-biopsy urine scores with ERSPC and PCPT multivariate risk calculator scores for men with GG1 at biopsy to post-RP pathology. Results Urine EPI scores were significantly lower in men with GG1 at biopsy than in men with > GG1 (p = 0.04), while there were no differences in multivariate risk scores used in standard clinical practice (p > 0.05). Further, EPI scores were significantly lower in men with GG1 at biopsy who remained GG1 post-RP compared to men upgraded to >= GG3 post-RP (p < 0.001). In contrast, none of the multiparametric risk calculators showed significant differences (p > 0.05). Men with GG1 at biopsy and EPI score < 15.6 had zero rate of upgrading to >= GG3 post-RP compared to 16.0% for EPI scores >= 15.6. Conclusions The EPI urine biomarker outperformed the multivariate risk calculators in a homogenous risk group of pre-biopsy men. The EPI score was associated with low-risk pathology post-RP, with potential implications on informing AS decisions.
引用
收藏
页码:983 / 989
页数:7
相关论文
共 27 条
[11]   Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer [J].
Klotz, Laurence ;
Vesprini, Danny ;
Sethukavalan, Perakaa ;
Jethava, Vibhuti ;
Zhang, Liying ;
Jain, Suneil ;
Yamamoto, Toshihiro ;
Mamedov, Alexandre ;
Loblaw, Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :272-U75
[12]  
Kretschmer, 2021, UROLOGE A, V60, P6
[13]   What is the best way not to treat prostate cancer? [J].
Leapman, Michael S. ;
Carroll, Peter R. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (02) :42-50
[14]   Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml-1) [J].
Liu, Jun ;
Wang, Zhi-Qian ;
Li, Min ;
Zhou, Ming-Yang ;
Yu, Yi-Fei ;
Zhan, Wei-Wei .
ASIAN JOURNAL OF ANDROLOGY, 2020, 22 (02) :213-216
[15]   Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone [J].
Liu, Junxiao ;
Dong, Biao ;
Qu, Wugong ;
Wang, Jiange ;
Xu, Yue ;
Yu, Shuanbao ;
Zhang, Xuepei .
SCIENTIFIC REPORTS, 2020, 10 (01)
[16]   Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies [J].
Margolis, Erik ;
Brown, Gordon ;
Partin, Alan ;
Carter, Ballentine ;
McKiernan, James ;
Tutrone, Ronald ;
Torkler, Phillipp ;
Fischer, Christian ;
Tadigotla, Vasisht ;
Noerholm, Mikkel ;
Donovan, Michael J. ;
Skog, Johan .
PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (02) :296-301
[17]   Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy [J].
McKiernan, James ;
Donovan, Michael J. ;
Margolis, Eric ;
Partin, Alan ;
Carter, Ballentine ;
Brown, Gordon ;
Torkler, Phillipp ;
Noerholm, Mikkel ;
Skog, Johan ;
Shore, Neal ;
Andriole, Gerry ;
Thompson, Ian ;
Carroll, Peter .
EUROPEAN UROLOGY, 2018, 74 (06) :731-738
[18]   A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy [J].
McKiernan, James ;
Donovan, Michael J. ;
O'Neill, Vince ;
Bentink, Stefan ;
Noerholm, Mikkel ;
Belzer, Susan ;
Skog, Johan ;
Kattan, Michael W. ;
Partin, Alan ;
Andriole, Gerald ;
Brown, Gordon ;
Wei, John T. ;
Thompson, Ian M., Jr. ;
Carroll, Peter .
JAMA ONCOLOGY, 2016, 2 (07) :882-889
[19]  
Mottet, 2021, EAU ANN C MIL 2021 E
[20]   MRI-guided active surveillance in prostate cancer: not yet ready for practice [J].
Ploussard, Guillaume ;
Renard-Penna, Raphaele .
NATURE REVIEWS UROLOGY, 2021, 18 (02) :77-78